After Searing Debate, FDA Clears Unproven Sarepta Drug

By Jeff Overley (September 19, 2016, 10:19 PM EDT) -- The U.S. Food and Drug Administration on Monday cleared a $300,000 drug from Sarepta Therapeutics for muscular dystrophy despite unproven benefits, capping an extraordinary review process that saw the agency's top drug regulator overrule scientists who opposed approval....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!